Patel: China and Australia join hands to explore big data solutions for precision therapy of hypertension

The Chinese Academy of Sciences Technology Consulting Institute (CASISD), Springer Nature Group China and the University of New South Wales Sydney are reaching an exciting new partnership. Research capabilities, including medical health.

帕特尔:中澳联手,探索高血压精准疗法大数据方案

“China and Australia are currently facing very similar health challenges.” Anushka Patel, chief scientist of the George Institute for Global Health, professor of medicine at the University of New South Wales, Sydney, said that 20 years ago, the main countries The disease is not the same, but now faces the common challenge of changing chronic disease prevention. The problems caused by chronic diseases are not only health problems, but also premature deaths and huge economic losses. These are the problems that chronic diseases face in both countries. Therefore, these two countries can conduct joint research in this field and find a better solution to the problem.

Do you still use medicine or technology? It is the purpose of exerting efficacy

Even in countries like Australia, only 50% of patients with high blood pressure are truly treated, and only 25% of hypertensive patients are really well controlled. Because doctor resources are limited, each doctor spends about 20 minutes on a patient. Therefore, it is difficult to fully understand the condition and give an effective intervention plan in a short period of time. The situation will be another matter. "To make full use of the advantages of current big data, artificial intelligence, etc., this situation can be changed very well by means of technology." Professor Patel said that all the cases before the patient can be extracted from the system first, followed by an algorithm. Calculate what interventions should be taken, whether it should be taken, whether it should be used for the second time, the third time, etc., including screening, efficacy testing, etc. can be achieved by relying on algorithms.

Committed to the management of cardiovascular disease for many years, Professor Patel actively promotes the traditional science of cognition of cardiovascular disease risk factor management, and has a tremendous impact on the subversive low-cost effective care of cardiovascular disease patients. “Drug research and development is one of the priorities of every clinician. However, the cycle of drug development is very long and the investment is huge. How to make good use of existing drugs becomes an effective way to improve the management level of patients with cardiovascular diseases. Ways.” While actively exploring the disease characteristics of patients in different regions and giving opinions on comprehensive medications, using mobile medical technology and other scientific means to improve patient compliance has become a focus of her research.

"No matter whether it is prescribed by a doctor or a patient, the compliance and accuracy are not enough, so even the best medicine can't achieve the desired effect. Through technology, we can make the existing drugs fully work on the patients needed, especially In some cross-disciplinary research, we can change the good help patients to do disease management work.” Professor Patel believes that the rise of mobile medical technology, for all kinds of chronic diseases, weight loss and other health problems that require long-term health intervention, Can have a very good effect. Therefore, her George Institute for Global Health and the University of New South Wales in Sydney are actively promoting the mobile medical intervention model for chronic diseases.

China's health management needs blowout, big data resources have obvious advantages

Chinese hypertensive patients have exceeded 330 million, and 130 million of them do not know that they have high blood pressure. At present, there are many drugs that can help patients effectively control the development of hypertension, however, they have not been fully and effectively used.

“The problem is not that there is no medicine, but that doctors and patients are not well aware of the condition and mismanagement.” Professor Patel believes that mobile medicine is a good way. At the same time, China’s population resource advantage can improve the accuracy of mobile medical applications. Help, for example, tens of thousands of samples in China can be used for clinical randomized trials, and the same sample may have only a few dozen in Australia. Due to the rich sample resources, doctors can carry out extensive testing and revision work, and obtain more accurate disease intervention methods based on a large data base. Therefore, China can provide such an opportunity to better test new drugs. Through such an international joint clinical experiment, not only can China and Australia benefit, but also more countries can benefit.

Australia has a wealth of experience in health management and is more scientific about the management of chronic diseases. These methods are very useful for helping Chinese doctors and chronically ill patients to control their disease development. "Our health management relies mainly on the support of doctors, patients, and family members. In the face of a large group of chronic diseases patients in China, relying on scientific and technological means can help them to more scientifically engage in chronic disease intervention."

In doing so, every hypertensive patient has an exclusive treatment plan.

Professor Patel has made extensive attempts to promote mobile medicine to achieve cardiovascular disease intervention. For example, can patients download APP from APPSTORE? Is there a uniform APP and advice for every patient?

“No! No! As a clinician, we know that each patient’s condition has its own characteristics, so the medication intervention must be different. Therefore, each APP is entered after the patient’s condition. A personalized management model is given for the patient's condition, which in turn provides personalized guidance for doctors who provide health management," said Professor Patel.

The time for patients to see a doctor is only about 10-20 minutes. Doctors need to give effective and accurate personalized interventions in such a short period of time. We hope to provide doctors with decision support by developing algorithms and help patients with hypertension to achieve disease screening through algorithms. And monitoring of the development of the disease. However, based on the professionalism of the medical treatment, this app will not be provided to the patients themselves. The pre-judgment given by each algorithm is for the doctor to provide a reference, and the doctors can give personalized diagnosis and treatment suggestions based on the overall health of the patient. .

Therefore, APP will not provide downloads in the open market, but will be provided by health management agencies. “Our partners we choose in China include a pension service company and Taikang Life Insurance, which provide users with pension and health management services.” The apps provided by these institutions will be used by patients, doctors, and family members. The entire algorithm is fine-tuned during the process to ensure that it is appropriate for each patient.

This app is not only for heart disease, cardiovascular disease, but also for other diseases, such as diabetes, as well as neurological problems; such as anxiety, depression and other symptoms, Professor Patel said.

Big data advantage, attract more quality partners for Chinese medical care!

Australia's hypertension disease management level is more advanced than China's, what attracts them to China?

“Many people in Australia still use credit cards and cash. China generally solves all problems with Alipay and WeChat. Therefore, the exploration and development of mobile technology and innovative use are places that Australia needs to learn. China actually belongs to this technology. A pioneering country," said Professor Patel.

With the rapid development of the Internet, big data, and artificial intelligence technologies, China has become a partner option that many European and American countries cannot ignore. Next, the rational and effective use of scientific and technological advantages will become the fast lane for the healthy development of China's medical care.

2-Piece Ostomy pouch MDK-BO-02 500ML

1-Piece Ostomy Pouch

A one-piece colostomy bags, drainable pouching system designed to be opened at the bottom when emptying. These colostomy bag machine are most suitable for colostomies or ileostomies. Ostomy bag colostomy barrier is a standard wear skin barrier that is gentle to the skin and allows for frequent pouch removal. To close the pouch, use the curved, beige clamp. Soft, beige disposable colostomy bag pouch panels on body side help provide comfort.

The features are soft and flex,standard wear, skin barrier, flat. The Chassis made in 100% hydrocolloid No tape border. Cut-to-fit skin barrier. Ultra-clear odor-barrier pouch film. Curved, beige pouch clamp. With comfortable ware pouch panel body side only. Not made with natural rubber latex.

Ostomy urostomy colostomy bag care products consist of sodium carboxymethylcellulose, adhesives made from medical hot melt adhesives, and separator paper or separators. Nursing equipment for ileum, colon, rectum or urethral stoma,The coloplast colostomy bag comes into contact with intact skin and intestinal lumen,Non-sterile supply. Colostomy bag reusable for stoma washing, care and collection of excreta and skin care around the stoma.

Use disposable colostomy bag, make sure the skin around the stoma is clean and dry before use. Remove the bags for colostomi from the package and separator or paper. Reshape the coloplast colostomy bag into the desired shape and size to fit the skin around the stoma. Apply the colostomy convatec bag to the skin around the stoma,adjust the shape of the paste again,Gently press so that it is firmly flat on the skin. Attach the stoma colostomy bag undercarriage to the stoma. The colostomy bag care can be peeled off the skin, don`t reuse. These one-piece-colostomy bag or two-piece-colostomy-bag are non-sterile product and is valid for three years under the condition of meeting the storage conditions.

1-Piece Ostomy Pouch,One Piece Ostomy Bags,One Piece Ostomy Pouch,1 Piece Ostomy Bag

Henan Maidingkang Medical Technology Co.,Ltd , https://www.mdkmedicales.com